New drug combo aims to control myeloma without transplant

NCT ID NCT04656951

Ongoing Disease control Sponsor: University of Cologne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests daratumumab (Darzalex) combined with other drugs as a first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. The goal is to see if this combination can achieve very good partial remission or better after 8 cycles, and then control the disease with maintenance therapy. If the cancer returns, patients will be retreated with daratumumab. The study involves 67 participants and is currently active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab (Darzalex) combined with bortezomib, cyclophosphamide, dexamethasone, and lenalidomide
What this could lead to: If successful, this could provide a treatment plan that controls multiple myeloma for longer without needing a stem cell transplant.
What could go wrong: This is a small, early-phase trial with only 67 participants, so results may not apply to everyone. The disease may still relapse despite treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

University of Cologne

Cologne, 50937, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.